Role of progesterone and other neuroactive steroids in anxiety disorders

References

• Kessler RC, McGonagle IKA, Nelson CB et al Lifetime and 12 months prevalence of DSM-III-R psychiatric disorders in the United States; results from the National Comorbidity Survey. Arch Gen Psychiatry 51,8–19 (1994).
   PubMed Web of Science ®Google Scholar
• Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am. PTchiatry157,669–682 (2000).
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Sisitsky T, Kessler RC et al The economic burden of anxiety disorders in the 1990s. I Clin. Psychiatry 60,427–435 (1999).
   Google Scholar
• Dick CL, Bland RC, Newman SC. Panic disorder. Acta Bychiatrica Scandinavia 376, 45–53 (1994).
   Web of Science ®Google Scholar
• Weissman MM, Bland RC, Canino GJ et al The cross-national epidemiology of panic disorder. Arch Gen. Psychiatry 54, 305–309 (1997).
   PubMed Web of Science ®Google Scholar
• Gater R, Tansella,M, Korten A et al Sex differences in the prevalence and detection of depressive and anxiety disorders in general healthcare settings. Arch. Gen. PTchiatry55, 405–413 (1998).
   PubMed Web of Science ®Google Scholar
• Faravelli C, Zucchi T, Viviani B et al. Epidemiology of social phobia: a clinical approach. Eur Psychiatry 15,17–24 (2000).
   PubMed Web of Science ®Google Scholar
• Yonkers KA. Anxiety symptoms and anxiety disorders: how are they related to premenstrual dysphoric disorders. J. Glitz Bychiatry58(Suppl), 62–69 (1997).
   Google Scholar
• Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JE Impact of pregnancy on panic disorder: a case series. I Clin. Psychiati y55, 284–288 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen LS, Sichel DA, Faraone SV et al Course of panic disorder during pregnancy and the puerperium: a preliminary study. PTchiatry39, 950–954 (1996).
   PubMedGoogle Scholar
• Northcott CJ, Stein MB. Panic disorder in pregnancy. I Clin. Psychiatry 55,539–542 (1994).
   PubMed Web of Science ®Google Scholar
• May W, Vallée M, Damaudéry M, Le Moal M. Potentiation of GABAergic neurotransmission by steroids. In: Contemporary Endocrinology' Neurosteroids: a New Regulatory Function in the Nervous System. Baulieu EE, Robel P, Schumacher M (Eds). Humana Press, Totowa, NJ, USA, 317–335 (1999).
   Google Scholar
• Purdy RII, Paul SM. Potentiation of GABAergic neurotransmission by steroids. In: Contemporary Endocrinology' Neumsteroids: a New Regulatory Function in the Nervous System. Baulieu EE, Robel P, Schumacher M. (Eds). Humana Press, Totowa, NJ, USA, 143–153 (1999).
   Google Scholar
• Mayo W, Vallee M, Darnaudry M, Le Moal M. Neurosteroids. Behavioral studies. In: Contemporary Endocrinology' Neumsteroids: a New Regulatory Function in the Nervous System. Baulieu EE, Robe LP, Schumacher M (Eds). Humana Press, Totowa, NJ, USA, 317–335 (1999).
   Google Scholar
• Bixo M, Anderson A, Windblad B, Purdy RII, Backstrome T Progesterone, 5a-pregnane-3,20-dione and 3a-hydroxy-5a-pregnan-20-one in specific regions of the human female brain in different endocrine states. Bmin Res. 764(1–2), 173–178 (1997).
   Google Scholar
• Chouinard G, Annable L, Fontain R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. PTchopharmacology77, 229–233 (1982).
   PubMedGoogle Scholar
• Ballenger JC, Burrows GD, DuPont RL et al Alprazolam in panic disorder and agoraphobia: results from a multicenter trial: I effcicacy in short-term treatment. Arch Gen. Bychiatry 45, 413–422 (1988).
   PubMedGoogle Scholar
• Davidson JR, Potts N, Ritchie E et al. Treatment of social phobia with clonazepam and placebo. I Clin. PTchopharmacology13,423–428 (1993).
   PubMed Web of Science ®Google Scholar
• Feltner DE, Robinson P, Janney C, Panse A. A placebo-controlled study of pregabalin treatment of social phobia. American College of Neuropsychopharmacology meeting, Hawaii, USA (1998).
   Google Scholar
• Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: a placebo-controlled study. Clin. PTchophalmacol. 19,341–348 (1999a).
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Janney CA, Feltner DE. Pregabalin, a novel agent, in the treatment of generalized anxiety disorder. American College of Neuropsychopharmacology Meeting Acapulco, Mexico (1999b).
   Google Scholar
• Nutt DJ, Glue P, Lawson CW, Wilson S. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine sensitivity in panic disorder. Arch. Gen PTchiatry 47,917–925 (1990).
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D. Reduced benzodiazepine sensitivity in panic disorder. Arch. Gen. Fiychiatry 47, 534–538 (1990).
   PubMed Web of Science ®Google Scholar
• Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABAA-benzodiazepine receptor binding in panic disorder. Preliminary results from a quantitative PET study. Arch. Gen Fiychtry55, 715–720 (1998).
   PubMedGoogle Scholar
• Bremner JD, Innis RB, White T et al Spect (I-123) Iomazenil measurement of the benzodiazepine receptor in panic disorder. PTchiatry 47, 96–106 (2000).
   PubMedGoogle Scholar
• Weizman R, Tanne Z, Granek M et al Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Fur. Phaimacol 138,289–292 (1987).
   Google Scholar
• Ferrarese C, Appollonio I, Frigo M et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr Scand 82,169–173 (1990).
   PubMed Web of Science ®Google Scholar
• Rocca P, Ferrero P, Gualerzi A et al. Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Bychiatr Scand. 84, 537–544 (1991).
   PubMedGoogle Scholar
• Cowley DS, Roy-Byrne PP, Hommer D et al. Benzodiazepine sensitivity in anxiety disorders. Biol. Psychiatry29, 57 (1991).
   Google Scholar
• Tiihonen J, Kuikka J, Rasanen P et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mal Psychiatry 2,463–471 (1997).
   PubMed Web of Science ®Google Scholar
• Malizia AL, Coupland NJ, Nutt DJ. Benzodiazepine receptor function in anxiety disorders. In: GABA Receptors and Anxiety: From Neurobiology to Treatment. Biggio G, Sanna E, Costa E (Eds). Raven Press, NY, USA, 115–133 (1995).
   Google Scholar
• Bitran D, Purdy RII, Kellogg CK. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol Biochem. &hay 45, 423–428 (1993).
   Google Scholar
• Bitran D, Schiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. I Aiumendocrinol 7, 171–177 (1995).
   Google Scholar
• •Demonstrates that allopregnanolone mediates the anxiolytic effect of progesterone at the level of the GABAA receptor.
   Google Scholar
• Picazo 0, Fernandez-Guasti A. Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation using the burying behavior test. Brain Res. 680, 135–141 (1995).
   Google Scholar
• Bradwejn J, Koszycki D, Schriqui C. Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder. Arch. Gen fiychiatry48, 603–607 (1991).
   PubMed Web of Science ®Google Scholar
• Abelson JL, Nesse M. Pentagastrin infusions in patients with panic disorder I. Symptoms and cardiovascular responses. Biol. Fiychiatry36, 73–83 (1994).
   PubMedGoogle Scholar
• Le Mellédo J-M, Ghandri JS, Lott P et al The effect of medroxyprogesterone pretreatment on the response to pentagastrin in female panic disorder patients. Psychiatry Res 2001, 237–242 (2001).
   Google Scholar
• Smith SS, Gong QH, Li X et al. Withdrawal from 3a-OH-5apregnan-20-one using a pseudopregnancy model alters tht kinetics of hippocampal GABAA_ gated current and increases the GABAA receptor a4 subunit in association with increased anxiety. Neurosci. 18,5275–5284 (1998).
   Google Scholar
• •Demonstrates that in rodents, fluctuations of allopregnanolone (which occur physiologically in women) modify the subunit composition of the GABAA receptor and consequently the receptor's pharmacology
   Google Scholar
• Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbituate-like modulators of the GABA receptor. Science 232,1004–1007 (1986).
   Google Scholar
• Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Frog: Neurobiol 38,379–395 (1992).
   Google Scholar
• Paul SM, Purdy RII. Neuroactive steroids. FASERJ 6,2311–2322 (1992).
   PubMed Web of Science ®Google Scholar
• Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3a-hydroxy-5 al3 pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Bmin Res. 561,157-161 (1991).
   Google Scholar
• Wieland S, Belluzzi JD, Stein L, Lan NC. Comparative behavioural characterization of the neuroactive steroids 3a0H,50-pregnan-20-one and 3a0H,50-pregnan-20-one in rodents. PTchopharmacology118, 65–71 (1995).
   PubMed Web of Science ®Google Scholar
• Patchev VK, Shoib M, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neumscience 62,265–271 (1994).
   PubMed Web of Science ®Google Scholar
• Patchev VK, Montkowski A, Rouskeva D, Koranyi L, Holsboer E Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioural and neuroendocrine consequences of adverse early life events. j Clin. Investigation 99, 962–966 (1997).
   PubMedGoogle Scholar
• •Demonstrate that the dramatic and long term effects of early stress on the hypothalarno-pituitary-adrenal (HPA) axis in rat pups can be reversed by administration of 3a,5B-THDOC, another progesterone derivative with potent activity at the level of the GABAA receptor.
   Google Scholar
• Akwa Y, Purdy RH, Koob GF, Britton KT The amygdala mediates the anxiolytic effect of the neurosteoid allopregnanolone in rat. &hay. Brain Res. 106,119–125 (1999).
   Google Scholar
• Bitran D, Dugan M, Renda P, Ellis R, Foley M. Anxiolytic effects of the neuroactive steroid pregnanolone (3a-OH,50-pregnan-20-one) after microinjection in the dorsal hippocampus and the lateral septum. Brain Res. 850,217-224 (1999).
   Google Scholar
• Fernandez-Guasti A, Picazo 0. Sexual differentiation modifies the allopragnanolone anxiolytic actions in rats. Bichoneumendocrinology24, 251–267 (1999).
   Google Scholar
• Bitran D, Foley M, Audette D, Leslie N, Frye CA. Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rats. Psychopharmacology151,64–71 (2000).
   Google Scholar
• Bitran D, Klibansky ZDA, Martin GA. The neurosteroid pregnanolone sulfate prevents the anxiogenic-like effect of 69Shekhar A, Keim SR. LY-354740, a potent 81 70Sajdyk TJ, Shekhar A. Excitatory amino acid receptors antagonists block the cardiovascular and anxiety responses elicited by gamma-aminobutyric acid A receptor blockade in the basolateral 83 amygdala of rats. J. Pharmacel Exp.Ther. 283, 969–77 (1997). inescable shock in the rat. fiychopharmacology151, 31–37 (2000).
   Google Scholar
• Barbaccia ML, Roscetti G, Trabucchi M et al. Isoniazid-induced inhibition of GABAergic transmission enhances neurosteroid content in the rat brain. Neurophatmacology35, 1299–1305 (1996).
   PubMedGoogle Scholar
• Carboni E, Wieland S, Lan NC, Gee KW Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety. Psychopharmacology126, 173–178 (1996).
   PubMed Web of Science ®Google Scholar
• Brot MD, Akwa Y, Purdy RII, Koob GF, Britton KT The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA-A receptors. Eur Pharmacel 325, 1–7 (1997).
   PubMed Web of Science ®Google Scholar
• Zimmerberg B, Rackow SH, George- Friedman IQ. Sex-dependent behavioural effects of the neurosteroid allopregnanolone in neonatal and adult rats after postnatal stress. Pharmacel Biochem. Behar,. 64, 717–724 (1999).
   Google Scholar
• Crawley J, Glowa JR, Majewska MD, Paul SM. Anxiolytic activity of an endogenous adrenal steroid. Brain Res. 398(2), 382–385 (1986).
   Google Scholar
• Wieland S, Lan C, Mirasedeghi S, Gee KW Anxiolytic activity of the progesterone metabolite 3a0H,50-pregnan-3a-ol-one. Brain Res. 565, 263–268 (1991).
   PubMed Web of Science ®Google Scholar
• Reddy DS, Kulkami SK. Differential anxiolytic effects of neurosteroids in the mirrored chamber behaviour test in mice. Brain Res. 752, 61–71 (1997).
   PubMedGoogle Scholar
• Femandez-Guasti A, Picazo 0. Flumazenil blocks the anxiolytic action of allopregnanolone. Eur. j Pharmacel 281, 113–115 (1995).
   Google Scholar
• Majewska MD, Schwartz RD. Pregnenolone-sulfate: an endogenous antagonist of the y-aminobutyric acid receptor complex in brain? Brain Res. 404, 355–360 (1997).
   Google Scholar
• Melchior CL, Ritzmann RE Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on the plus-maze. Phatmacel Biochem Behav 48, 893–897 (1994).
   PubMedGoogle Scholar
• Majewska MD, Demirgören S, Spivak CE, London ED. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res. 526, 143–146 (1990).
   PubMed Web of Science ®Google Scholar
• Baulieu E-E, Robel P Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive steroids. Proc. Nail Acad. USA 95, 4089–4091 (1998).
   PubMed Web of Science ®Google Scholar
• Semeniuk T, Ghandri JS, LeMelledo J-M. Neuroactive steroids plasma levels in patients with generalized anxiety disorder. J. Neuropsychiatry Clin. 13, 396–398 (2001).
   Google Scholar
• Heydari B, Le Melledo J-M. Decreased serum levels of pregnenolone sulfate in patients with generalized social phobia. (2004) (In Press).
   Google Scholar
• Genazzani AR, Petragalia F, Bernardi F et al. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J. Clin Endocrine" Metab. 83, 2099–2103 (1998).
   Google Scholar
• Wang M, Wahlström G, Backström T The regional brain distribution of the neurosteroids pregnenolone and pregnenolone sulfate following intravenous infusion. J. Steroid Biochem. MolBiol. 62, 199–306 (1997).
   Google Scholar
• Wu FS, Gibbs TT, Farbs DH. Pregnenolone sulfate: a positive allosteric modulator at the NMDA receptor. Mol. Pharmacol. 40, 333–336 (1991).
   Google Scholar
• Kash SF, Tecott LH, Hodge C, Baekkeskov S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 96, 1698–703 (1999).
   Google Scholar
• Shekhar A, Keim SR. LY-354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39, 1139–1146 (2000).
   PubMed Web of Science ®Google Scholar
• Sajdyk TJ, Shekhar A. Excitatory amino acid receptors antagonists block the cardiovascular and anxiety responses elicited by gamma-aminobutyric acid A receptor blockade in the basolateral amygdala of rats. J. Pharmacol. Exp.Ther. 283, 969–77 (1997).
   PubMed Web of Science ®Google Scholar
• Spivak B, Maayan R, Kotler M et al. Elevated circulatory levels of GABA-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psycho" Med 30, 1227–1231 (2000).
   Google Scholar
• Strohle A, Romeo E, di Michele F et al. GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am .j Psychiatry159, 145–147 (2002).
   Google Scholar
• Barbaccia ML, Roscetti G, Trabucchi M et al Time-dependent changes in rat brain neuroactive steroid concentrations and GABA-A receptor function after acute stress. Neumendocrinology63, 166–172 (1996a).
   PubMed Web of Science ®Google Scholar
• Barbaccia M, Roscetti G, Bolacchi F et al. Stress-induced increase in brain neuroactive steroids: antagonism with abecarnil. Phannacel Biochern Behav 54, 205–210 (1996).
   PubMedGoogle Scholar
• Tait G, McManus K, Chrapko W Lara N, Bellavance F, Le Mellédo J-M. Neuroactive steroid response to pentagastrin in patients with panic disorder and healthy volunteers. Psychoneutvendoainology27, 417–429 (2002).
   Google Scholar
• Deci PA, Lydiard B, Santos AB, Arana GW. Oral contraceptive and panic disorder. J. Clin P9rhiatry53, 163–165 (1992).
   Google Scholar
• Ushiroyama T, Okamoto Y, Toyoda K, Sugimoto 0. A case of panic disorder induced by oralcontraceptive. Acta Obstet. Cynecol. Scand 71, 78–80 (1992).
   Google Scholar
• Price WA, Heil D. Estrogen-induced panic attacks. Psychosomatics 29, 433–435 (1988).
   PubMedGoogle Scholar
• Korhonen S, Saarijarvi S, Alto M. Estradiol treatment of panic disorder in a fertile-aged woman. Human fiychophatmacel 10, 485–486 (1995).
   Google Scholar
• Concas A, Follesa P, Porcu P, Sogliano C, Biggio G. Oral contraceptives decrease cerebral concentrations of neurosteroids and modify GABAA receptors gene expression. Neuropsychopharmacology23, S24 (2000).
   Google Scholar
• Van Megen HJGM. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology114, 449–455 (1994). McManus K, Tait GR, Bellavance F, Le Mellédo J-M. Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin. j Affect. Olson:" 66, 273–279 (2001).
   Google Scholar
• Abelson JL, Liberian I. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neurop9thophatmacology 21, 485–494 (1999).
   Google Scholar
• Purdy RII, Morrow AL, Moore PH Jr, Paul SM. Stress-induced elevations of y-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl Acad. Sci. USA 88, 4553–4557 (1991).
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Ainj Psychiatry 153, 1444–1449 (1996). www.future-drugs.com
   Google Scholar